Tema Etfs LLC Acquires 11,585 Shares of AnaptysBio, Inc. $ANAB

Tema Etfs LLC lifted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 105.6% during the 4th quarter, HoldingsChannel reports. The fund owned 22,560 shares of the biotechnology company’s stock after acquiring an additional 11,585 shares during the quarter. Tema Etfs LLC’s holdings in AnaptysBio were worth $1,094,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Federated Hermes Inc. boosted its holdings in AnaptysBio by 2,236.6% in the 3rd quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock valued at $5,920,000 after purchasing an additional 185,053 shares during the period. Panagora Asset Management Inc. acquired a new position in shares of AnaptysBio during the 2nd quarter worth approximately $741,000. Assenagon Asset Management S.A. increased its holdings in shares of AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the period. 683 Capital Management LLC increased its holdings in shares of AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ raised its position in shares of AnaptysBio by 333.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock valued at $4,446,000 after buying an additional 111,668 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Piper Sandler boosted their price target on AnaptysBio from $67.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. Stifel Nicolaus upped their target price on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of AnaptysBio in a research report on Monday. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $80.10.

AnaptysBio Trading Up 1.7%

NASDAQ ANAB opened at $57.68 on Friday. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -110.92 and a beta of 0.40. The firm’s 50 day simple moving average is $56.08 and its 200 day simple moving average is $44.42. AnaptysBio, Inc. has a 1 year low of $15.40 and a 1 year high of $68.39.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The business had revenue of $108.25 million during the quarter, compared to the consensus estimate of $87.09 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its board has authorized a share repurchase plan on Friday, March 27th that authorizes the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Eric J. Loumeau sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total value of $540,000.00. Following the sale, the insider directly owned 12,835 shares of the company’s stock, valued at $693,090. This trade represents a 43.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director John P. Schmid sold 20,645 shares of the firm’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the sale, the director directly owned 31,622 shares in the company, valued at $1,774,310.42. This trade represents a 39.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 130,838 shares of company stock worth $6,491,529. 33.50% of the stock is owned by company insiders.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.